List of Excipients in Branded Drug OLUMIANT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Eli Lilly and Company	OLUMIANT	baricitinib	0002-4182	CELLULOSE, MICROCRYSTALLINE
Eli Lilly and Company	OLUMIANT	baricitinib	0002-4182	CROSCARMELLOSE SODIUM
Eli Lilly and Company	OLUMIANT	baricitinib	0002-4182	FERRIC OXIDE RED
Eli Lilly and Company	OLUMIANT	baricitinib	0002-4182	MAGNESIUM STEARATE
Eli Lilly and Company	OLUMIANT	baricitinib	0002-4182	MANNITOL

Last updated: August 17, 2026

Executive summary: Olumiant (baricitinib) uses a compact, conventional immediate-release tablet platform built around mannitol, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, and a film coat. The formulation has low excipient complexity, no lactose, and no liquid or device-dependent delivery component. Its commercial opportunity is therefore concentrated in generic tablet manufacturing, excipient supply optimization, pediatric and hospital-use presentations, and differentiated global packaging rather than in a high-barrier formulation franchise. Baricitinib remains a small-molecule product, so generic ANDA and Paragraph IV activity is the principal erosion risk; biosimilar regulation does not apply.

Olumiant Excipient Strategy and Commercial Opportunities

What is the Olumiant formulation and which excipients does it use?

Olumiant is an immediate-release, film-coated tablet containing baricitinib, a selective Janus kinase inhibitor with activity against JAK1 and JAK2. The U.S. product is available in 1 mg, 2 mg, and 4 mg strengths. The dosage form is designed for once-daily oral administration and does not require a modified-release matrix, lipid vehicle, solubilizing system, or delivery device.[1]

Olumiant excipient composition

Formulation element	Publicly identified excipient or function	Commercial relevance
Diluent and bulking agent	Mannitol	Supports tablet mass and produces a lactose-free formulation
Binder and compression aid	Microcrystalline cellulose	Supports direct compression and mechanical strength
Disintegrant	Croscarmellose sodium	Promotes rapid tablet breakup and immediate release
Lubricant	Magnesium stearate	Reduces ejection force and tooling adhesion
Film coating	Hypromellose-based coating system with pigments and opacifying agents	Provides color differentiation, protection, and swallowability
Active ingredient	Baricitinib	Low-dose, highly potent API requiring blend-uniformity control

The precise quantities and supplier grades are not generally disclosed in the commercial label. FDA labeling identifies the inactive ingredients, while manufacturing specifications, particle-size distributions, coating parameters, and process controls remain proprietary.[1,2]

The formulation is commercially efficient because it relies on widely available pharmaceutical excipients. It does not depend on a specialized polymer, nanoformulation, amorphous dispersion, osmotic system, or complex granulation process. That structure lowers manufacturing barriers for generic developers but increases the importance of process control for low-dose content uniformity.

Why does Olumiant use mannitol, microcrystalline cellulose, and croscarmellose sodium?

The excipient system is consistent with a direct-compression or low-complexity immediate-release tablet strategy.

Mannitol

Mannitol provides bulk in a low-dose product and can improve mouthfeel relative to some alternative fillers. It is also useful where a sponsor wants to avoid lactose. For a 1 mg tablet, the API represents a small fraction of total tablet mass, making uniform distribution a primary development issue. Mannitol particle size, morphology, and flow properties can affect segregation during blending and compression.

Commercial opportunity exists for:

• Co-processed mannitol-cellulose systems.
• Low-segregation grades for potent, low-dose APIs.
• Direct-compression mannitol with controlled particle-size distribution.
• Excipient systems that reduce blend sampling variability.
• Global grades with harmonized compendial status.

Microcrystalline cellulose

Microcrystalline cellulose contributes compactibility and tablet strength. It can compensate for the poor compressibility that may arise when mannitol is used as the principal diluent. Grade selection affects:

• Tensile strength.
• Disintegration time.
• Ejection force.
• Tablet weight variability.
• Sensitivity to compression speed.
• Moisture-related behavior.

A generic manufacturer can often use the same excipient classes while changing supplier, grade, or processing parameters. Those changes still require pharmaceutical development and comparative dissolution work.

Croscarmellose sodium

Croscarmellose sodium provides rapid disintegration through swelling and wicking. Its performance depends on particle size, substitution level, incorporation method, and whether the material is added intragranularly, extragranularly, or entirely in a direct-compression blend.

For a once-daily immediate-release JAK inhibitor, rapid disintegration supports predictable dissolution without the need for an extended-release polymer. Excipient vendors can differentiate through:

• Faster disintegration at lower use levels.
• Improved performance under high compression force.
• Lower batch-to-batch variability.
• Better compatibility with mannitol-rich blends.

Magnesium stearate

Magnesium stearate is a conventional lubricant, but over-lubrication can slow wetting and dissolution. The critical process variables include blending time, lubricant surface area, concentration, and shear exposure. Generic manufacturers should control lubricant addition and blending more tightly than the simple ingredient list might suggest.

What formulation patents protect Olumiant?

The principal commercial protection for Olumiant is expected to come from baricitinib compound, composition, and method-of-use patent rights rather than from a highly differentiated excipient platform. Conventional excipients such as mannitol, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate generally provide limited standalone patent protection.

Patent categories relevant to Olumiant

Patent category	Strategic role	Generic exposure
Baricitinib compound patents	Protect the active molecule	Primary date for earliest small-molecule entry
Pharmaceutical composition patents	Protect combinations, dosage forms, or formulation parameters	May require non-infringement or validity analysis
Method-of-use patents	Cover rheumatoid arthritis, alopecia areata, COVID-19, or other indications	Relevant to skinny-label and induced-infringement analysis
Manufacturing patents	Cover API synthesis, intermediates, salts, or purification	Can increase API sourcing and DMF risk
Pediatric or dosing patents	Protect age groups, dosing regimens, or treatment sequences	Often relevant to label carve-outs
Trademark and regulatory exclusivity	Protect commercial identity or delay approval	Separate from patent expiry

The FDA Orange Book is the controlling public source for listed U.S. patents and regulatory exclusivity associated with approved drug products. Listings and patent-term calculations can change through litigation, patent-term adjustment, pediatric extensions, or regulatory updates.[3]

Olumiant’s excipient list alone is unlikely to prevent a generic from designing around the formulation. A generic applicant may use the same excipient classes, substitute equivalent grades, or develop a different immediate-release blend if it meets quality and bioequivalence requirements.

When does Olumiant lose exclusivity and face generic entry?

Olumiant faces small-molecule generic risk rather than biosimilar risk. Generic applicants can submit an Abbreviated New Drug Application with Paragraph IV certifications against listed patents. A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic.[4]

Generic entry scenarios

Scenario	Commercial effect
No Paragraph IV litigation	Entry may follow approval and expiry of applicable regulatory or patent barriers
Paragraph IV notice followed by litigation	A 30-month stay may delay approval, subject to statutory exceptions
Settlement with authorized generic or delayed entry	Erosion may be staged rather than immediate
Skinny-label approval	Generic may omit patented indications if the remaining label supports approval
At-risk launch	Generic enters before final resolution and assumes infringement damages risk
Formulation redesign	Generic avoids selected composition claims while retaining tablet economics

The highest-risk product is a conventional 1 mg, 2 mg, or 4 mg immediate-release tablet with the same route and dosing frequency. Such a product can potentially rely on standard bioequivalence pathways and does not need to reproduce every inactive ingredient.

A generic developer may have a stronger commercial position if it can obtain approval for all non-patented indications while carving out a protected method of use. This issue is material because Olumiant has multiple approved or authorized therapeutic uses, including rheumatoid arthritis, severe alopecia areata, and certain hospitalized COVID-19 patients.[1,5]

What is the FDA regulatory status of Olumiant?

FDA approved Olumiant for adults with moderately to severely active rheumatoid arthritis after inadequate response or intolerance to one or more tumor necrosis factor antagonist therapies. FDA later approved baricitinib for adults with severe alopecia areata. The product also received FDA authorization and subsequent regulatory treatment for certain hospitalized COVID-19 patients requiring respiratory support.[1,6]

Key FDA milestones

Milestone	Date or status
U.S. approval for rheumatoid arthritis	2018
FDA emergency authorization for hospitalized COVID-19 patients	2020
U.S. approval for severe alopecia areata	2022
U.S. regulatory status	Approved small-molecule oral tablet
Generic pathway	ANDA
Biosimilar pathway	Not applicable
Orange Book relevance	Applicable

The product’s regulatory breadth increases commercial value but also creates method-of-use patent complexity. Generic applicants may seek approval for a subset of indications if use patents remain enforceable.

What commercial opportunities exist in Olumiant excipients?

The largest near-term opportunity is not a novel excipient patent. It is a supply and manufacturing platform that improves consistency, cost, and regulatory portability.

1. Low-dose blend-uniformity systems

Baricitinib tablets contain a potent API at low strengths. Excipient systems that reduce segregation can create value through:

• Improved content uniformity.
• Shorter blending cycles.
• Lower weight variability.
• Reduced rejected-batch risk.
• Better performance on high-speed tablet presses.

Co-processed mannitol and microcrystalline cellulose are commercially relevant if they provide more consistent flow and compaction than separate excipients.

2. Lactose-free immediate-release platforms

Olumiant’s public formulation is compatible with a lactose-free positioning. A generic manufacturer can retain that profile while developing a platform for other low-dose kinase inhibitors, immunomodulators, or cardiovascular compounds.

The platform opportunity is strongest when one excipient system supports several strengths without major changes to tablet weight or process settings.

3. Pediatric and hospital presentations

The standard commercial product is a tablet. Pediatric treatment and hospital administration create potential demand for:

• Dispersible tablets.
• Oral suspensions.
• Unit-dose sachets.
• Hospital-ready blister packaging.
• Water-dispersible tablets for patients unable to swallow.

A liquid or dispersible product would require new stability, dosing uniformity, microbial-control, container-closure, and palatability work. It could also trigger separate formulation patent claims or regulatory exclusivity, depending on jurisdiction and development timing.

4. Film-coating and color-coding systems

The three tablet strengths require clear visual differentiation to reduce medication errors. Coating suppliers can compete on:

• Pigment uniformity.
• Lower coating weight.
• Faster drying.
• Reduced tablet sticking.
• Improved moisture protection.
• Color consistency across global sites.

A ready-to-use coating system can reduce scale-up time for generic manufacturers, particularly where the product is manufactured at multiple facilities.

5. Global excipient harmonization

A global product may require different pharmacopoeial documentation, allergen statements, residual-solvent controls, and permitted-colorant assessments. Suppliers that offer the same functional excipient grade across the United States, European Union, Japan, and emerging markets can reduce regulatory variation.

The commercial advantage is strongest for suppliers that can provide:

• DMF support.
• Change-control commitments.
• Multi-site manufacturing.
• Pharmacopoeial compliance.
• Extractables and leachables packages.
• Consistent particle-size and moisture specifications.

How strong is the Olumiant formulation patent estate?

The formulation estate appears strategically less defensible than the compound and clinical-use estate because the marketed tablet uses conventional excipients and an uncomplicated release profile. Patent strength should be assessed claim by claim, not from the ingredient list.

Factors supporting patent strength

• Narrow claims directed to a specific baricitinib solid form.
• Defined impurity limits or stability performance.
• Specific particle-size or dissolution parameters.
• Manufacturing claims that improve purity or yield.
• Method claims tied to approved treatment populations.
• Patent-term adjustment or pediatric extension.

Factors weakening formulation exclusivity

• Broad use of standard excipients.
• Availability of alternative immediate-release compositions.
• Lack of a complex delivery system.
• Ability to omit selected method-of-use indications.
• Potential prior art involving conventional tablet blends.
• Limited need to reproduce the branded formulation exactly.

A generic may therefore challenge the listed patents while developing an equivalent tablet with different excipient grades. The formulation does not need to be identical to Olumiant’s formulation to satisfy ANDA requirements.

Which companies control Olumiant and its commercial rights?

Olumiant is associated with Eli Lilly and Company. Baricitinib was discovered in collaboration with Incyte, and the commercial relationship includes rights and economic interests that vary by territory and indication.[7,8]

The licensing structure matters for:

• Royalty allocation.
• Patent enforcement decisions.
• Authorized-generic strategy.
• Regional commercialization.
• Settlement economics.
• Revenue sharing after generic entry.

Lilly’s commercial position is strongest in markets where it controls regulatory approvals, distribution, and the principal branded indication portfolio. Incyte’s participation gives the asset a separate strategic dimension because patent, royalty, and geographic rights can affect transaction value.

How does Olumiant compare with competing JAK inhibitors?

Olumiant competes with other oral JAK inhibitors and with biologic disease-modifying antirheumatic drugs. Relevant competitors include tofacitinib, upadacitinib, filgotinib in certain markets, and other immunomodulatory agents used in rheumatoid arthritis or alopecia areata.

Product	Active ingredient	Dosage form	Excipient opportunity
Olumiant	Baricitinib	Immediate-release tablet	Low-dose blend control, dispersible or pediatric formats
Xeljanz	Tofacitinib	Immediate-release and extended-release tablets	Release-platform and formulation differentiation
Rinvoq	Upadacitinib	Extended-release tablet	More complex release-control and formulation barriers
Biologic competitors	Various biologics	Injection or infusion	Device, protein stability, and cold-chain opportunities

Olumiant’s simple immediate-release platform may make it easier to manufacture than extended-release JAK products. The tradeoff is lower formulation-based protection and potentially greater generic substitutability.

What revenue exposure exists when Olumiant faces generic competition?

Revenue exposure depends on indication mix, geographic patent terms, payer substitution, and the timing of generic approvals. The product has multiple indications, which can slow total erosion if some uses remain protected or if prescribing is concentrated in specialties with slower substitution.

Revenue-risk drivers

1. U.S. generic approval and launch timing.
2. Patent litigation and settlement terms.
3. Generic availability in rheumatoid arthritis versus alopecia areata.
4. International reference pricing.
5. Authorized-generic deployment.
6. Hospital purchasing for COVID-19 use.
7. Physician willingness to switch stable patients.
8. Competitive pricing from other JAK inhibitors and biologics.

A conventional generic launch could produce rapid price compression in the highest-volume tablet strengths. The branded product may preserve value through indication-specific labeling, safety monitoring, specialty distribution, patient-support programs, and supply reliability, but these defenses are weaker than patent exclusivity.

What manufacturing and intellectual-property barriers affect generic Olumiant?

The API is more important than the excipient system for manufacturing risk. Generic developers must control:

• API polymorph or solid-state form.
• Impurity profile.
• Residual solvents.
• Particle-size distribution.
• Blend uniformity at low dose.
• Tablet hardness and friability.
• Dissolution across strengths.
• Photostability and moisture stability.
• Film-coat color matching.
• Scale-up reproducibility.

Manufacturing patents covering baricitinib intermediates or processes may create a practical barrier even when the final tablet formulation is easy to reproduce. A generic developer can seek an alternative synthesis, but it must demonstrate adequate impurity control and regulatory acceptability.

Geographic risk also differs by market. U.S. entry depends on Orange Book-listed patents and Hatch-Waxman procedures. European entry depends on national validation, unitary or European patent rights, supplementary protection certificates, and national litigation. Emerging-market entry can occur earlier but may face local registration, API sourcing, and enforcement constraints.

What is the commercial outlook for Olumiant excipient suppliers?

The most attractive opportunity is a platform sale to generic and contract manufacturers rather than a single-product exclusive supply agreement. Suppliers can position a formulation package around low-dose immediate-release tablets with:

• Mannitol-cellulose co-processing.
• Fast-disintegrating croscarmellose.
• Controlled lubrication.
• Ready-to-use film coating.
• Regulatory documentation.
• Demonstrated dissolution robustness.
• Multi-site supply continuity.

Novel excipient approval is unlikely to be necessary for the core generic opportunity. Established compendial excipients reduce regulatory risk and shorten development timelines. A genuinely novel excipient would add toxicology, regulatory, and supply-chain burdens that are difficult to justify for a conventional tablet unless it enables a superior pediatric, liquid, or modified-release product.

Key Takeaways

• Olumiant is a conventional immediate-release baricitinib tablet in 1 mg, 2 mg, and 4 mg strengths.
• Its public excipient system includes mannitol, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, and a film coat.
• The central technical challenge is low-dose content uniformity, not complex drug release.
• Conventional excipients create limited formulation-based exclusivity.
• Generic ANDA and Paragraph IV activity is the main U.S. erosion risk.
• Biosimilar competition does not apply because baricitinib is a small molecule.
• The strongest excipient opportunities are co-processed direct-compression systems, rapid disintegrants, film coatings, and pediatric or hospital-ready presentations.
• API synthesis, solid-state control, impurity management, and method-of-use patents may create more meaningful barriers than the marketed excipient combination.
• A generic formulation can differ from the branded tablet while remaining eligible for an ANDA.
• Geographic patent, SPC, litigation, and settlement conditions will determine the timing of commercial erosion.

FAQs

Can a generic manufacturer use the same Olumiant excipients?

Yes. Generic manufacturers can use the same excipient classes if the formulation meets quality, stability, dissolution, and bioequivalence requirements. They do not generally need to duplicate the branded supplier or exact grade.

Is Olumiant suitable for an oral liquid formulation?

Potentially, but an oral liquid would require separate development for solubility, suspension uniformity, chemical stability, microbial control, palatability, and container closure. It would not be a simple substitution for the existing tablet.

Does Olumiant contain lactose?

The U.S. labeling identifies mannitol, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate among the inactive ingredients and does not identify lactose in the tablet core.[1,2]

Can excipient selection avoid Olumiant patent infringement?

Excipient substitution may help avoid narrow composition claims, but it does not avoid compound patents, manufacturing patents, or method-of-use claims. A complete freedom-to-operate analysis must evaluate the relevant claims and jurisdiction.

Is there an authorized generic opportunity for Olumiant?

An authorized generic could protect some volume after generic entry by offering a lower-priced version under the branded sponsor’s control. Its commercial value would depend on licensing economics, patent settlements, channel strategy, and the timing of independent ANDA approvals.

References

1. U.S. Food and Drug Administration. (2024). Olumiant (baricitinib) prescribing information. Eli Lilly and Company.

2. National Library of Medicine. (2024). DailyMed: Olumiant, baricitinib tablet, film coated. U.S. National Library of Medicine.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (2017). ANDA submissions: Refuse-to-receive standards guidance for industry. Center for Drug Evaluation and Research.

5. European Medicines Agency. (2023). Olumiant: European public assessment report. Committee for Medicinal Products for Human Use.

6. U.S. Food and Drug Administration. (2022). FDA approves baricitinib for severe alopecia areata. Center for Drug Evaluation and Research.

7. Eli Lilly and Company. (2024). Annual report.

8. Incyte Corporation. (2024). Annual report.